The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

START YOUR PATIENTS ON OTEZLA TODAY

OTEZLA offers convenient, oral dosing1

Treatment begins with a 5-day titration1:

otezla-30-mg-starter-pack

After the titration period, the maintenance dose of OTEZLA is 30 mg twice daily for most patients1

  • This titration is intended to reduce gastrointestinal symptoms associated with initial therapy
  • OTEZLA can be taken with or without food
  • Patients should not split, crush, or chew the tablet

The dose of OTEZLA should be reduced to 30 mg once daily in patients with severe renal impairment1*:

  • For such patients, it is recommended that OTEZLA be titrated using only the AM schedule shown above

*Creatinine clearance (CrCl) <30 mL/min estimated by the Cockcroft-Gault equation.

Reference:

  1. OTEZLA Summary of Product Characteristics. Amgen Europe B.V. Winthontlaan 6 N 3526 KV Utrecht Netherlands; 2019.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.